BACKGROUND: A healthy cornea is reliant on a distinct population of stem cells (SC) that replace damaged or aging epithelium throughout life. Depletion of the SC pool or damage to the niche can result in a blinding and painful condition known as limbal-SC deficiency (LSCD). Although current treatment strategies for reconstituting the ocular surface for patients suffering LSCD are promising, they are complicated by transferring autologous or allogeneic progenitors in the presence of animal, human, and synthetic products. We report on the safe and efficacy of a unique autologous SC transfer technique that utilizes an Food and Drug Administration-approved contact lens (CL) as the SC substrate and carrier for patients with LSCD. METHODS: Three patients with LSCD due to aniridia (n=1) and posttreatment for recurrent ocular surface melanoma (n=2) were included. Limbal (n=2) or conjunctival biopsies (n=1) were harvested and progenitors expanded ex vivo on therapeutic CLs in the presence of autologous serum. Cell-laden CLs were transferred to the patient's corneal surface and clinical outcome measures were recorded (follow-up range, 8-13 months). RESULTS: A stable transparent corneal epithelium was restored in each patient. There was no recurrence of conjunctivalization or corneal vascularization, and a significant improvement in symptom score occurred in all patients. Best-corrected visual acuity was increased in all eyes after the procedure. CONCLUSION: Ex vivo expansion of ocular surface epithelium in the presence of autologous serum and transplantation with the aid of a soft CLs is a promising new technique capable of achieving ocular surface rehabilitation.
BACKGROUND: A healthy cornea is reliant on a distinct population of stem cells (SC) that replace damaged or aging epithelium throughout life. Depletion of the SC pool or damage to the niche can result in a blinding and painful condition known as limbal-SC deficiency (LSCD). Although current treatment strategies for reconstituting the ocular surface for patients suffering LSCD are promising, they are complicated by transferring autologous or allogeneic progenitors in the presence of animal, human, and synthetic products. We report on the safe and efficacy of a unique autologous SC transfer technique that utilizes an Food and Drug Administration-approved contact lens (CL) as the SC substrate and carrier for patients with LSCD. METHODS: Three patients with LSCD due to aniridia (n=1) and posttreatment for recurrent ocular surface melanoma (n=2) were included. Limbal (n=2) or conjunctival biopsies (n=1) were harvested and progenitors expanded ex vivo on therapeutic CLs in the presence of autologous serum. Cell-laden CLs were transferred to the patient's corneal surface and clinical outcome measures were recorded (follow-up range, 8-13 months). RESULTS: A stable transparent corneal epithelium was restored in each patient. There was no recurrence of conjunctivalization or corneal vascularization, and a significant improvement in symptom score occurred in all patients. Best-corrected visual acuity was increased in all eyes after the procedure. CONCLUSION: Ex vivo expansion of ocular surface epithelium in the presence of autologous serum and transplantation with the aid of a soft CLs is a promising new technique capable of achieving ocular surface rehabilitation.
Authors: Jeanie Chui; Minas T Coroneo; Lien T Tat; Roger Crouch; Denis Wakefield; Nick Di Girolamo Journal: Am J Pathol Date: 2011-02 Impact factor: 4.307
Authors: Gregory M Cooper; Emily L Durham; James J Cray; Michael R Bykowski; Gary E DeCesare; Melissa A Smalley; Mark P Mooney; Phil G Campbell; Joseph E Losee Journal: Plast Reconstr Surg Date: 2011-01 Impact factor: 4.730
Authors: Jon R Eidet; Ida G Fostad; Marie A Shatos; Tor P Utheim; Øygunn A Utheim; Sten Raeder; Darlene A Dartt Journal: Invest Ophthalmol Vis Sci Date: 2012-05-14 Impact factor: 4.799
Authors: Karl David Brown; Suet Low; Indumathi Mariappan; Keren Maree Abberton; Robert Short; Hong Zhang; Savitri Maddileti; Virender Sangwan; David Steele; Mark Daniell Journal: Tissue Eng Part A Date: 2014-01-23 Impact factor: 3.845